In the fragmented landscape of modern healthcare, the journey of a patient with a rare disease is often characterized by a repetitive, exhausting cycle: clinical intake forms, disconnected diagnostic tests, and the constant loss of longitudinal data as they move between providers and clinical trials. For the roughly 300 million people globally suffering from rare conditions, this lack of data continuity is more than an administrative burden—it is a significant barrier to life-saving innovation.
Two Irish health tech innovators, Cushla and Clirinx, are taking a decisive step to dismantle these silos. By announcing a strategic merger, the companies aim to transform how patient data is managed, preserved, and utilized. The union promises to replace the "start-from-zero" approach with a unified, patient-owned health record that persists across the entire clinical journey.
Main Facts: A New Infrastructure for Patient Sovereignty
The core of this acquisition involves Cushla—a platform dedicated to patient data ownership—absorbing Clirinx, a specialized clinical research platform. By integrating Cushla’s user-centric data architecture with Clirinx’s proprietary patient identification system, the combined entity aims to create a "golden record" for patients.
Unlike traditional electronic health records (EHRs) which are often locked within proprietary hospital systems, this new model gives patients control over their information. Crucially, the platform utilizes a unique clinical research ID that remains constant as a patient moves between different trials. This allows for the seamless aggregation of health data, ensuring that years of clinical history are not discarded when a specific study concludes.
David Soden, an Irish go-to-market strategist leading the capital raise for the merger, emphasized that the goal is to shift the power dynamic. "If you found out tomorrow you had a rare disease, you have a 5% chance of finding out there’s a treatment," Soden said during a recent industry event at the Guinness Enterprise Centre in Dublin. "That’s a horrendous place to be."
The Chronology of an Industry Pain Point
The genesis of this merger lies in the lived experience of Gerry Nesbitt, the founder of Clirinx. As a patient living with primary biliary cholangitis (PBC)—a chronic autoimmune disease that causes the progressive destruction of the liver’s bile ducts—Nesbitt experienced firsthand the frustration of the current research ecosystem.
- The Silo Era: Nesbitt observed that once a clinical trial concludes, the data generated is often archived or lost, becoming inaccessible to the patient or future researchers.
- The Clirinx Solution: Nesbitt developed a clinical research ID to provide a "thread" that follows the patient, ensuring their data history remains intact from one trial to the next.
- The Strategic Alignment: Cushla identified that the key to unlocking patient-controlled health data lay in the identification protocols pioneered by Clirinx.
- The Merger Initiation: Cushla moved to acquire Clirinx to combine its front-end patient data platform with the back-end infrastructure required for large-scale clinical research.
- Capital Mobilization: Currently, the company is in the final stages of securing the funding necessary to formalize the acquisition and scale operations into the U.S. market.
Supporting Data and Market Potential
The urgency of this merger is underscored by the current state of rare disease research. While rare diseases are individually infrequent, they collectively affect 300 million people worldwide. The primary bottleneck in drug development, according to industry experts, is the "recruitment-and-retention" trap.
Researchers currently struggle to maintain contact with trial participants. When a trial ends, the follow-up is often nonexistent. Consequently, the next research team attempting to study the same disease must start the recruitment process from scratch, wasting millions of dollars and precious time.
The combined Cushla-Clirinx entity has already secured €555,000 in initial funding from Irish investors. Their first major test case involves the American Liver Foundation, which represents approximately 50,000 patients in the United States. By building a registry that allows these patients to maintain their own records, the platform is creating a longitudinal dataset that is highly attractive to pharmaceutical companies.
Official Responses and Ethical Guardrails
One of the most sensitive aspects of modern health tech is data privacy. In an era where patient data is often treated as a commodity, the company is taking pains to differentiate its business model from data brokers.
"We don’t sell the raw patient data to pharma. We don’t sell it to anybody," Soden stated. He clarified that the company’s business model relies on "governed access to de-identified, composite datasets." In this model, pharmaceutical companies do not purchase the individual’s identity or private health files; instead, they purchase access to aggregated, anonymized insights that can help them design better, more effective trials.
Furthermore, the company is implementing a novel revenue-sharing model. They intend to formalize partnerships with patient advocacy groups, promising to funnel a portion of pharmaceutical revenue back into these organizations. This serves a dual purpose: it provides the advocacy groups with the resources they need to continue supporting their patient communities, and it ensures that the company remains incentivized to keep the patient—not the pharma buyer—at the center of the business.
Implications: The Shift Toward the U.S. Market
While the merger is rooted in Ireland, the company’s near-term sights are set squarely on the United States. Soden cited the U.S. regulatory environment as being significantly more conducive to scaling than the fragmented systems found across Europe. In the U.S., the ability to partner with large, national patient advocacy groups allows for faster deployment of the technology.
The implications of this move are twofold:
For the Pharmaceutical Industry
For Big Pharma, the platform represents a way to reduce the immense costs associated with patient attrition. By having access to a pre-verified, longitudinal cohort of patients, companies can conduct clinical trials more efficiently. The promise of "governed access" also mitigates the compliance and reputational risks associated with handling raw, identifiable health data.
For the Rare Disease Patient
For the patient, the impact is existential. A unified, patient-owned record means that the medical history gathered today can inform the treatments of tomorrow. It removes the burden of the patient having to act as the "messenger" between disconnected doctors and researchers. By owning their data, patients become active partners in the research process rather than mere subjects.
Future Outlook
As the company moves toward closing its current funding round, the primary challenge will be execution. Scaling a patient-data platform requires not just technical prowess, but the establishment of deep trust with both the medical community and patient advocacy groups.
Soden’s declaration that the company aims to be "less of a billing mechanism" and more of a patient-empowerment tool will be tested as they integrate into the U.S. market. If successful, this Irish merger could set a new global standard for how health data is handled, moving the industry toward a model where patients are the true owners of their clinical legacy.
The transition from a "siloed" system to an "integrated" one is long overdue. By placing the power of data back into the hands of those who need it most, Cushla and Clirinx are not just merging companies—they are building the infrastructure for a more transparent, efficient, and patient-centric future in medicine.
Editor’s note: This report is based on discussions held during a trip hosted by Enterprise Ireland. The organization invited MedCity News Associate Editor Katie Adams to attend in Dublin. Travel expenses were covered by Enterprise Ireland, but company officials had no input in the editorial coverage provided herein.
